Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15246057rdf:typepubmed:Citationlld:pubmed
pubmed-article:15246057lifeskim:mentionsumls-concept:C0008013lld:lifeskim
pubmed-article:15246057lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:15246057lifeskim:mentionsumls-concept:C0278348lld:lifeskim
pubmed-article:15246057pubmed:issue3lld:pubmed
pubmed-article:15246057pubmed:dateCreated2004-7-12lld:pubmed
pubmed-article:15246057pubmed:abstractTextThe chemokine/chemokine receptor network is an essential part of an intricate system of immunosurveillance and homeostasis, it promotes or suppresses neovascularization, affects and regulates directly or indirectly growth and metastasis of malignant cells. Numerous studies have been conducted to harness this network as therapeutic agents for cancer to redress the chemokine balance and control angiogenesis and tumour growth and metastasis. Second generation of immunotherapeutics and chemoattractant-based vaccines use chemokines and chemoattractant peptides to elicit antitumor immunity by a specific targeting and modulating subsets of effector leukocytes, including professional antigen presenting cells.lld:pubmed
pubmed-article:15246057pubmed:languageenglld:pubmed
pubmed-article:15246057pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15246057pubmed:citationSubsetIMlld:pubmed
pubmed-article:15246057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15246057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15246057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15246057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15246057pubmed:statusMEDLINElld:pubmed
pubmed-article:15246057pubmed:monthJunlld:pubmed
pubmed-article:15246057pubmed:issn1044-579Xlld:pubmed
pubmed-article:15246057pubmed:authorpubmed-author:BiragynAryaAlld:pubmed
pubmed-article:15246057pubmed:authorpubmed-author:CosciaMartaMlld:pubmed
pubmed-article:15246057pubmed:issnTypePrintlld:pubmed
pubmed-article:15246057pubmed:volume14lld:pubmed
pubmed-article:15246057pubmed:ownerNLMlld:pubmed
pubmed-article:15246057pubmed:authorsCompleteYlld:pubmed
pubmed-article:15246057pubmed:pagination209-18lld:pubmed
pubmed-article:15246057pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:15246057pubmed:meshHeadingpubmed-meshheading:15246057...lld:pubmed
pubmed-article:15246057pubmed:meshHeadingpubmed-meshheading:15246057...lld:pubmed
pubmed-article:15246057pubmed:meshHeadingpubmed-meshheading:15246057...lld:pubmed
pubmed-article:15246057pubmed:meshHeadingpubmed-meshheading:15246057...lld:pubmed
pubmed-article:15246057pubmed:meshHeadingpubmed-meshheading:15246057...lld:pubmed
pubmed-article:15246057pubmed:meshHeadingpubmed-meshheading:15246057...lld:pubmed
pubmed-article:15246057pubmed:meshHeadingpubmed-meshheading:15246057...lld:pubmed
pubmed-article:15246057pubmed:meshHeadingpubmed-meshheading:15246057...lld:pubmed
pubmed-article:15246057pubmed:meshHeadingpubmed-meshheading:15246057...lld:pubmed
pubmed-article:15246057pubmed:meshHeadingpubmed-meshheading:15246057...lld:pubmed
pubmed-article:15246057pubmed:year2004lld:pubmed
pubmed-article:15246057pubmed:articleTitleCancer immunotherapy with chemoattractant peptides.lld:pubmed
pubmed-article:15246057pubmed:affiliationLaboratorio di Ematologia Oncologica, Divisione di Ematologia dell'Universita' di Torino, CeRMS, Azienda Ospedaliera San Giovanni Battista, Torino, Italy.lld:pubmed
pubmed-article:15246057pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15246057pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15246057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15246057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15246057lld:pubmed